1
|
Magalon J, Abellan-Lopez M, Brandin T, Degioanni C, Grimaud F, Veran J, Dignat George F, Bertrand B, Sabatier F. Response to Universal Classification System for Platelet-Rich Plasma (PRP): A Method to define the variables in PRP production. Burns 2020; 47:489-490. [PMID: 32843239 DOI: 10.1016/j.burns.2020.07.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 07/22/2020] [Indexed: 10/23/2022]
Affiliation(s)
- J Magalon
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France
| | - M Abellan-Lopez
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - T Brandin
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France
| | - C Degioanni
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France
| | - F Grimaud
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France
| | - J Veran
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France
| | | | - B Bertrand
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France.
| | - F Sabatier
- Cell Therapy Laboratory, Hôpital de la Conception, AP-HM, INSERM CIC BT, 1409, Marseille, France; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France
| |
Collapse
|
2
|
Bembo F, Eraud J, Philandrianos C, Bertrand B, Silvestre A, Veran J, Sabatier F, Magalon G, Magalon J. Combined use of platelet rich plasma and micro-fat in sport and race horses with degenerative joint disease: preliminary clinical study in eight horses. Muscles Ligaments Tendons J 2019. [DOI: 10.32098/mltj.02.2016.06] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- F. Bembo
- Veterinary Clinic, Luynes France
| | - J. Eraud
- Plastic Surgery Department, La Conception University Hospital, Marseille, France
| | - C. Philandrianos
- Plastic Surgery Department, La Conception University Hospital, Marseille, France
| | - B. Bertrand
- Plastic Surgery Department, La Conception University Hospital, Marseille, France
| | - A. Silvestre
- Radiology Department, Bordeaux Merignac Sports Clinic, Merignac, France
| | - J. Veran
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France
| | - F. Sabatier
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France
| | - G. Magalon
- Plastic Surgery Department, La Conception University Hospital, Marseille, France
| | - J. Magalon
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, La Conception University Hospital, Marseille, France
| |
Collapse
|
3
|
Beylerian M, Lazaro M, Magalon J, Veran J, Darque A, Grimaud F, Stolowy N, Beylerian H, Sabatier F, Hoffart L. [Autologous serum tears: Long-term treatment in dry eye syndrome]. J Fr Ophtalmol 2018; 41:246-254. [PMID: 29602451 DOI: 10.1016/j.jfo.2017.11.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 11/11/2017] [Accepted: 11/17/2017] [Indexed: 10/17/2022]
Abstract
INTRODUCTION Dry eye disease is a multifactorial pathology of the ocular surface. The high incidence of this pathology, as well as its significant impact on quality of life and vision and its financial cost, makes it a real public health problem. While the treatment of mild cases is generally simple and effective, treatment of severe forms is often disappointing. The use of autologous serum tears (AST) represents a therapeutic alternative for the most severe cases. The purpose of our study is to evaluate the efficacy of long-term AST treatment in patients with severe dry eye disease refractory to conventional treatment or secondary to systemic diseases such as Sjögren's syndrome or Graft versus Host disease (GVH), or ocular pathologies such as neurotrophic keratitis, chemical burns and ocular cicatricial pemphigoid. PATIENTS AND METHODS This is a monocentric retrospective observational study conducted on 47 patients, with 83 eyes treated with autologous serum eye drops for isolated or secondary dry eye disease at the Marseille Public Hospitals between April 2014 and April 2017. The patients' subjective symptoms (ocular surface disease index [OSDI] score), their degree of satisfaction and the side effects were collected using questionnaires. Tear Break Up Time (BUT) and Schirmer scores were noted. A clinical evaluation based on fluorescein staining (Oxford score) was carried out prior to treatment with AST at P0 followed by 5 periods: P1 (between 1 and 3 months), P2 (3 to 9 months), P3 (9 to 15 months), P4 (15 months to 24 months), and P5 (>24 months). RESULTS Out of the 83 eyes treated, the mean age was 54.39±21.56. There were 20 males (42.55 %) and 27 females (57.44 %); treatment indications consisted mainly of 25.53 % GVH, 21.27 % severe dry eye disease and 19.14 % Sjögren syndrome. The mean duration of follow-up was 9.82 months±15.50. The OSDI score decreased by 19.32 points±29.37 (P<0.05) between P0 and P1 and by 23.06 points±18.41 (P<0.05) between P0 and P4. The Oxford clinical score showed a significant decrease by the third month of treatment, between P0 and P2, by 1.32 points±1.76 (P<0.05). The Schirmer test and the BUT also showed an improvement in dry eye symptoms over time with AST, significantly at P1 (P<0.05). DISCUSSION Complementary biological analyzes on the composition of AST are under way in order to identify predictive factors of effectiveness; patients not responding to AST treatment might respond to allogeneic serum from healthy donor cord blood. CONCLUSION On this first series of 83 eyes treated with ASD, clinical efficacy was noted in most of the patients. No infectious complications were reported, and the satisfaction rate was very high.
Collapse
Affiliation(s)
- M Beylerian
- Service d'ophtalmologie, CHU de Hôpital La Timone, 264, rue Saint-Pierre, 13385 Marseille, France.
| | - M Lazaro
- Pharmacie, CHU Hôpital La Conception, 13005 Marseille, France
| | - J Magalon
- Laboratoire de cultures et de thérapies cellulaires (LCTC), CHU de La Conception, 13005 Marseille, France
| | - J Veran
- Laboratoire de cultures et de thérapies cellulaires (LCTC), CHU de La Conception, 13005 Marseille, France
| | - A Darque
- Pharmacie, CHU Hôpital La Conception, 13005 Marseille, France
| | - F Grimaud
- Pharmacie, CHU Hôpital La Conception, 13005 Marseille, France
| | - N Stolowy
- Service d'ophtalmologie, CHU de Hôpital La Timone, 264, rue Saint-Pierre, 13385 Marseille, France
| | - H Beylerian
- Service d'ophtalmologie, CHU hôpital Gui-De-Chauliac, 34000 Montpellier, France
| | - F Sabatier
- Laboratoire de cultures et de thérapies cellulaires (LCTC), CHU de La Conception, 13005 Marseille, France
| | - L Hoffart
- Service d'ophtalmologie, CHU de Hôpital La Timone, 264, rue Saint-Pierre, 13385 Marseille, France
| |
Collapse
|
4
|
Mesguich Batel F, Bertrand B, Magalon J, François P, Velier M, Veran J, Mallet S, Jouve E, Sabatier F, Casanova D. [Treatment of wrinkles of the upper lip by emulsified fat or "Nanofat": Biological and clinical study about 4 cases]. ANN CHIR PLAST ESTH 2017; 63:31-40. [PMID: 29157877 DOI: 10.1016/j.anplas.2017.10.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Accepted: 10/09/2017] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Emulsified fat injection showed its interest in aesthetic facial surgery. The adipose tissue harvested is mechanically emulsified and filtered. The suspension obtained is injected into the dermis through small diameter needles (27 to 30 gauges). The objective of our study was to evaluate the biological composition of emulsified fat and its clinical effectiveness in the treatment of peri-oral wrinkles in 4 patients aged 50 to 59 years. MATERIAL AND METHOD Each patient received an intradermal injection of emulsified fat in the peri-oral wrinkles prepared from abdominal fat under local anesthesia. The cell viability, stromal vascular fraction (FVS) composition in emulsified fat and the adipocyte differentiation capacity of mesenchymal stem cells (MSC) were studied. The clinical results were evaluated by standardized photographs, 3D microphotography, confocal microscopy, and self-evaluation of patient satisfaction over a period of 4 months. RESULTS The biological study of the emulsified fat found a lysis of all the adipocytes. The mean number of FVS cells was 126,330±2758 cells by cc of emulsified fat with preserved cell viability (85.1±6.84 %) and a good proportion of regeneratives cells (18.77±6.2 %). The clinical study found a tendency to decrease the volume of wrinkles on standardized photography and 3D microphotography no significative. Patients were satisfied with treatment with an average score of 7±1.15/10 to 4 months. CONCLUSION Intradermal injection of emulsified fat seems to be an interesting treatment of face wrinkles. Our study has shown its safety, but additional studies seems necessary to confirm its clinical efficacy.
Collapse
Affiliation(s)
- F Mesguich Batel
- Service de chirurgie plastique, hôpital de La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France.
| | - B Bertrand
- Service de chirurgie plastique, hôpital de La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France; UMRS-1076 Inserm, vascular research center of Marseille, université Aix-Marseille, 13005 Marseille, France
| | - J Magalon
- UMRS-1076 Inserm, vascular research center of Marseille, université Aix-Marseille, 13005 Marseille, France; Inserm CICBT-1409, laboratoire de culture et de thérapie cellulaire, hôpital de La Conception, université Aix-Marseille, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - P François
- UMRS-1076 Inserm, vascular research center of Marseille, université Aix-Marseille, 13005 Marseille, France; Inserm CICBT-1409, laboratoire de culture et de thérapie cellulaire, hôpital de La Conception, université Aix-Marseille, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - M Velier
- UMRS-1076 Inserm, vascular research center of Marseille, université Aix-Marseille, 13005 Marseille, France; Inserm CICBT-1409, laboratoire de culture et de thérapie cellulaire, hôpital de La Conception, université Aix-Marseille, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - J Veran
- Inserm CICBT-1409, laboratoire de culture et de thérapie cellulaire, hôpital de La Conception, université Aix-Marseille, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - S Mallet
- Service de dermatologie, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - E Jouve
- Unité de pharmacométrie CIC-CPCET, service de pharmacologie clinique et pharmacovigilance, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France; Service d'évaluation médicale, hôpital de la Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - F Sabatier
- UMRS-1076 Inserm, vascular research center of Marseille, université Aix-Marseille, 13005 Marseille, France; Inserm CICBT-1409, laboratoire de culture et de thérapie cellulaire, hôpital de La Conception, université Aix-Marseille, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - D Casanova
- Service de chirurgie plastique, hôpital de La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| |
Collapse
|
5
|
Ghazouane R, Bertrand B, Philandrianos C, Veran J, Abellan M, Francois P, Velier M, Orneto C, Piccerelle P, Magalon J. What About the Rheological Properties of PRP/Microfat Mixtures in Fat Grafting Procedure? Aesthetic Plast Surg 2017. [PMID: 28639068 DOI: 10.1007/s00266-017-0905-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Fat grafting has emerged as a reference procedure in daily plastic surgery practice. Unpredictable fat resorption is the main clinical problem. For this purpose, the addition of PRP to enhance fat revascularization is now an easy and popular procedure. However, no consensus exists regarding the respective volume of fat and PRP used to obtain the ideal mixture. This study investigated the rheological properties of microfat mixed with different proportions of PRP. Results obtained were compared with commercialized hyaluronic acid fillers. METHODS Microfat and PRP preparations were performed using standardized techniques. Lipoaspirate residue and blood were obtained from six patients undergoing aesthetic facial microlipofilling. Elastic modulus G' and tan δ (proportion of elasticity versus fluidity) were obtained for the following conditions: microfat alone and microfat mixed with 10, 30 or 50% of PRP. RESULTS An expected decrease in elastic modulus was observed by adding increase volumes of PRP. Two groups of products with different rheological properties were considered based on statistical differences highlighted regarding the value of G'. Mean tan δ varied from 0.20 ± 0.04 (microfat alone) to 0.28 ± 0.08 (50% microfat/50% PRP). Microfat mixed with 10% of PRP presents consistency comparable to stiffer fillers, whereas microfat mixed with 30 or 50% corresponds to softer fillers. CONCLUSION Rheological differences were highlighted given the proportion of PRP added to the microfat. Further studies assessing the impact of increased doses of platelets in microfat/PRP mixtures on clinical outcomes should also be investigated. Our findings will help clinicians to choose a mixture that meets their specific needs for a given indication. NO LEVEL ASSIGNED This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Collapse
|
6
|
Abstract
Vocal fold microstructure is complex and can be affected by laryngeal microsurgery, inducing scarring that prevents mechanical uncoupling of epithelium and muscle, leading to vibration disorder and disabling dysphonia. Treatment options presently are few, and often without efficacy for vibration, having only an impact on volume to reduce glottal closure defect. The present review of the literature had two aims: (i) to report the current state of the literature on cell therapy in vocal fold scarring; and (ii) to analyze the therapeutic interest of the adipose-derived stromal vascular fraction in the existing therapeutic armamentarium. A PubMed® search conducted in September 2016 retrieved English or French-language original articles on the use of stem cells to treat vocal fold scarring. Twenty-seven articles published between 2003 and 2016 met the study selection criteria. Mesenchymal stem cells were most widely used, mainly derived from bone marrow or adipose tissue. Four studies were performed in vitro on fibroblasts, and 18 in vivo on animals. End-points comprised: (i) scar analysis (macro- and micro-scopic morphology, viscoelastic properties, extracellular matrix, fibroblasts); and (ii) assessment of stem cell survival and differentiation. The studies testified to the benefit of mesenchymal stem cells, and especially those of adipose derivation. The stromal vascular fraction exhibits properties that might improve results by facilitating production logistics.
Collapse
Affiliation(s)
- A Mattei
- Aix Marseille université, 13000 Marseille, France; Service d'oto-rhino-laryngologie et chirurgie cervicofaciale, La Conception, Assistance publique-Hôpitaux de Marseille, 147, boulevard Baille, 13005 Marseille, France.
| | - J Magalon
- VRCM Inserm UMR 1076, faculté de pharmacie de Marseille, Aix Marseille université, 27, boulevard Jean-Moulin, 13385 Marseille cedex 5, France; Inserm CBT-1409, laboratoire de culture et thérapie cellulaire, La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - B Bertrand
- Service de chirurgie plastique et réparatrice, La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - C Philandrianos
- Service de chirurgie plastique et réparatrice, La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - J Veran
- Inserm CBT-1409, laboratoire de culture et thérapie cellulaire, La Conception, Assistance publique-Hôpitaux de Marseille, 13005 Marseille, France
| | - A Giovanni
- Service d'oto-rhino-laryngologie et chirurgie cervicofaciale, La Conception, Assistance publique-Hôpitaux de Marseille, 147, boulevard Baille, 13005 Marseille, France; CNRS, laboratoire parole et langage, Aix Marseille université, 5, avenue Pasteur, 13100 Aix-en-Provence, France
| |
Collapse
|
7
|
Guillaume-Jugnot P, Daumas A, Magalon J, Sautereau N, Veran J, Magalon G, Sabatier F, Granel B. State of the art. Autologous fat graft and adipose tissue-derived stromal vascular fraction injection for hand therapy in systemic sclerosis patients. Curr Res Transl Med 2016; 64:35-42. [PMID: 27140597 DOI: 10.1016/j.retram.2016.01.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 01/04/2016] [Indexed: 01/27/2023]
Abstract
Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microvascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from stromal vascular fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
Collapse
Affiliation(s)
- P Guillaume-Jugnot
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France
| | - A Daumas
- Service de médecine interne, gériatrie et thérapeutique, hôpital de la Timone, AP-HM, 13385 Marseille cedex 05, France
| | - J Magalon
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - N Sautereau
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France
| | - J Veran
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - G Magalon
- Service de chirurgie plastique et réparatrice, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - F Sabatier
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France; Inserm UMR 1076 Vascular Research Centre of Marseille, Aix-Marseille université, 13385 Marseille cedex 05, France
| | - B Granel
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France; Inserm UMR 1076 Vascular Research Centre of Marseille, Aix-Marseille université, 13385 Marseille cedex 05, France.
| |
Collapse
|
8
|
Magalon J, Chateau AL, Bertrand B, Louis ML, Silvestre A, Giraudo L, Veran J, Sabatier F. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med 2016; 2:e000060. [PMID: 27900152 PMCID: PMC5117023 DOI: 10.1136/bmjsem-2015-000060] [Citation(s) in RCA: 198] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/01/2016] [Indexed: 11/26/2022] Open
Abstract
Background/aim Significant biological differences in platelet-rich plasma (PRP) preparations have been highlighted and could explain the large variability in the clinical benefit of PRP reported in the literature. The scientific community now recommends the use of classification for PRP injection; however, these classifications are focused on platelet and leucocyte concentrations. This presents the disadvantages of (1) not taking into account the final volume of the preparation; (2) omitting the presence of red blood cells in PRP and (3) not assessing the efficiency of production. Methods On the basis of standards classically used in the Cell Therapy field, we propose the DEPA (Dose of injected platelets, Efficiency of production, Purity of the PRP, Activation of the PRP) classification to extend the characterisation of the injected PRP preparation. We retrospectively applied this classification on 20 PRP preparations for which biological characteristics were available in the literature. Results Dose of injected platelets varies from 0.21 to 5.43 billion, corresponding to a 25-fold increase. Only a Magellan device was able to obtain an A score for this parameter. Assessments of the efficiency of production reveal that no device is able to recover more than 90% of platelets from the blood. Purity of the preparation reveals that a majority of the preparations are contaminated by red blood cells as only three devices reach an A score for this parameter, corresponding to a percentage of platelets compared with red blood cells and leucocytes over 90%. Conclusions These findings should provide significant help to clinicians in selecting a system that meets their specific needs for a given indication.
Collapse
Affiliation(s)
- J Magalon
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, CIC BT 1409, Marseille, France; Vascular Research Center of Marseille, Aix-Marseille University, Marseille, France
| | - A L Chateau
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, CIC BT 1409, Marseille, France; Vascular Research Center of Marseille, Aix-Marseille University, Marseille, France
| | - B Bertrand
- Plastic Surgery Department , Hôpital de la Conception, AP-HM , Marseille , France
| | - M L Louis
- ICOS, Sport and Orthopedics Surgery Institute , Marseille , France
| | - A Silvestre
- Radiology Department , Bordeaux Merignac Sports Clinic , Merignac , France
| | - L Giraudo
- Cell Culture and Therapy Laboratory , Hôpital de la Conception, AP-HM, CIC BT 1409 , Marseille , France
| | - J Veran
- Cell Culture and Therapy Laboratory , Hôpital de la Conception, AP-HM, CIC BT 1409 , Marseille , France
| | - F Sabatier
- Cell Culture and Therapy Laboratory, Hôpital de la Conception, AP-HM, CIC BT 1409, Marseille, France; Vascular Research Center of Marseille, Aix-Marseille University, Marseille, France
| |
Collapse
|
9
|
Magalon J, Daumas A, Veran J, Magalon G, Rossi P, Granel B, Sabatier F. Autologous Adipose Tissue-Derived Cells: Are We Talking About Adipose Derived Stem Cells, Stromal Vascular Fraction, or Coleman Fat Grafting? Cell Transplant 2015; 24:2667-8. [PMID: 25715080 DOI: 10.3727/096368915x687552] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Affiliation(s)
- J Magalon
- Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | | | | | | | | | | | | |
Collapse
|
10
|
Guillaume-Jugnot P, Daumas A, Jouve E, Truillet R, Mallet S, Serratrice J, Swiader L, Veran J, Dignat-George F, Sabatier F, Magalon G, Granel B. Évaluation à 1 an de l’injection sous-cutanée de la fraction vasculaire stromale autologue d’origine adipeuse au niveau des doigts chez les patients atteints de sclérodermie systémique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Veran J, Farruggia R, Paret B. [Surgical treatment of the paralytic leprous foot. Apropos of 8 cases treated in New Caledonia]. Acta Leprol 1981; 85:93-7. [PMID: 6805240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
12
|
Mercier J, Dessaigne S, Gavend MR, Etzensperger P, Veran J. [Pharmacodynamic study of an antispasmodic and tranquilizing combination recommended in the treatment of digestive ulcers]. Pathol Biol 1967; 15:441-6. [PMID: 4864902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|